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In order to clarify the role played by immunologically de- 
rived cytokines in dermal connective tissue synthesis and 
degradation, we investigated the effect of human recombi- 
nant (hu-r) interleukin (IL) l-alpha and beta, hu-r tumor 
necrosis factor (TNF)-alpha and beta, hu-r IL 2, and hu-r 
granulocyte-macrophage colony-stimulating factor (GM- 
CSF) on the production of collagen, glycosaminoglycan, fi- 
bronectin, and collagenase activity by three lines of cultured 
human adult dermal fibroblasts. Our results show that 24- 
72 h treatment of confluent fibroblast cultures with IL l- 
alpha or beta or TNF-alpha or beta causes concentration (1 to 
1 X lo4 U/ml) dependent increases in collagen, glycosami- 
noglycan, and collagenase activity production, but decreases 
in fibronectin production. In contrast, treatment with IL 2 and 
GM-CSF had no effect on fibroblast functions. The data 
show that IL l-alpha and beta and TNF-alpha and beta dif- 
ferentially regulate fibroblast functions, and that increases in 
catabolic functions like collagenase activity production are 
more than tenfold greater than increases in anabolic func- 
tions like collagen production. When these results are con- 
sidered along with other reports, they suggest that IL 1 and 
TNF may play predominately a catabolic role in situ during 
dermal fibrotic res 
production and in B 
onses by directly inhibiting fibronectin 
irectly causing the degradation of colla- 
gen and glycosaminoglycan by significantly increasing der- 
ma1 fibroblast elaboration of collagenase and proteoglycanase 
activities.] Invest Dermatol92:699- 706, 1989 
F ibroblasts are responsible for the production and mainte- nance of the connective tissue matrix. Under basal con- ditions, the growth and synthetic activities of resident fibroblasts are of a limited nature and are likely con- trolled only by interaction with native connective tissue 
matrix components [1,2]. However, following either traumatic or 
pathologic tissue injury, resident fibroblasts appear to undergo a 
metabolic activation as cultured fibroblasts derived from sites of 
ongoing connective tissue metabolism exhibit elevated activities. 
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Abbreviations: 
DMR Dulbecco’s modified Eagle’s medium 
dpm: disintegrations per minute 
FCS: fetal calf serum (heat inactivated) 
GM-CSF: granulocyte-macrophage colony stimulating factor 
hu-r: human-recombinant 
IFN: interferon 
IL interleukin 
SD: standard deviation 
TGF: transforming growth factor 
TNF: tumor necrosis factor 
Fibroblasts derived from sites of anabolic pathologic fibrosis, such as 
keloid or scleroderma skin, dis lay activated phenotypes character- 
ized by increased production o P the connective tissue matrix compo- 
nents, collagens [3-71, glycosaminoglycans [4,8,9], and fibronectin 
[7], while fibroblasts derived from sites of catabolic pathologic fi- 
brosis, such as rheumatoid synovium or cartilage, produce increased 
amounts of connective tissue degrading enzymes like collagenase 
and other neutral proteases, as well as elevated quantities of prosta- 
glandin E, [lo]. Unfortunately, fibroblasts derived from traumatic 
wound tissue have seldom been studied, although granulation tissue 
fibroblasts reportedly differ from normal in the amount and charac- 
ter of glycosaminoglycans secreted [ 1 l]. 
Studies investigating the mechanisms responsible for fibroblast 
activation have recently focused on the role played by fibroblast- 
stimulatory cytokines as the early inflammatory phase of fibrotic 
responses is characterized by the infiltration of injured connective 
tissue by platelets, neutrophils, monocytes/macrophages, and/or T 
lymphocytes [12-141. While evidence of the presence of fibro- 
blast-stimulatory cytokines in situ is limited [15- 171, numerous in 
vitro studies demonstrate that cytokines can stimulate the growth, 
directional migration, and/or connective tissue matrix component 
synthesis/catabolism of cultured fibroblasts. To date, cytokmes re- 
ported to stimulate fibroblast functions in vitro include: transform- 
ing growth factor (TGF)-beta, which is produced by platelets, mon- 
ocytes/macrophages and T lym hocytes 
growth factor from platelets an B 
[ 18 - 211; platelet-derived 
monocytes/macrophages [20,22- 
241; interleukin (IL)-1, tumor necrosis factor (TNF)-alpha and 
other less defined monokines from monocytes/macrophages [25 - 
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301; TGF-alpha, epidermal growth factor, and other less defined 
cytokines from platelets [20,31,32]; TNF-beta several less defined 
fibroblast-stimulatory cytokines from T lymphocytes [33 - 371 or 
neutrophils [38]; and other well defined cytokines such as acidic and 
basic fibroblast growth factor and somatomedin C, whose cellular 
sources are uncertain [23,39]. 
Of all the fibroblast-stimulatory cytokines reported, monocyte/ 
macrophage-derived IL 1 has been the most extensively studied, 
especially in regard to its effect on synovial fibroblasts and chondro- 
cytes. IL 1 has been reported to increase all studied synovial fibro- 
blast and chondrocyte functions, including growth [40], collagen 
production [26,41] glycosaminoglycan production [42], fibronectin 
production [26], collagenase production [27,43], proteoglycanase 
production [43], and prostaglandin E, production [27,29]. The abil- 
ity of IL 1 to elevate multiple functions of synovial fibroblasts and 
chondrocytes strongly suggests that IL 1 plays a role in the degrada- 
tion of joint connective tissue seen in arthritic diseases. However, 
the role of IL 1 in dermal fibrotic diseases, such as keloids or sclero- 
derma, or in normal dermal wound repair is less certain, as the effect 
of IL 1 on dermal fibroblast function has not yet been comprehen- 
sively studied. Although it has long been known that IL 1 increases 
adult and infant foreskin dermal fibroblast growth [25], it has only 
recently been reported that IL 1 affects other functions of infant 
foreskin [29,44] and adult dermal fibroblasts [27]. 
In this report, we have studied the effect of highly purified sam- 
ples of human recombinant DNA-derived (hu-r) IL I-alpha and IL 
l-beta on three previously uninvestigated human adult dermal 
fibroblast functions (collagen, glycosaminoglycan, and fibronectin 
production) and one previously investigated function (collagenase 
activity production), in order to clarify the role IL 1 plays in adult 
dermal connective tissue synthesis and degradation. We similarly 
investigated the effect of hu-r TNF-alpha and beta as TNF-alpha 
reportedly increases the growth, collagenase activity production, 
and prostaglandin Ea production of infant foreskin dermal fibro- 
blasts [28,29], while TNF-beta has been reported to increase the 
growth of infant foreskin fibroblasts and the glycosaminoglycan 
production of lung fibroblasts [33,34]. The effects of two other 
cytokines, hu-r IL 2 and hu-r granulocyte-macrophage colony- 
stimulating factor (GM-CSF) were also studied in order to deter- 
mine if other mediators involved in the immunologic cytokine net- 
work also play a role in regulating dermal connective metabolism. 
Our results demonstrate that IL 1 alpha and beta, and TNF-alpha 
and beta differentially regulate the four studied fibroblast functions, 
increasing collagen, glycosaminoglycan, and collagenase activity 
production but decreasing fibronectin production, while IL 2 and 
GM-CSF had no effect on any dermal fibroblast function studied. 
MATERIALS AND METHODS 
Cytokines Hu-r interferon (IFN)-alpha, (SCH30500; specific ac- 
tivity, 1.2 X 10s U/mg protein) from Escherichia colt’ was kindly 
supplied by Schering Corporation (Kenilworth, NJ). Hu-r-E. coli- 
derived TNF-alpha (5.0 X IO’ Ujmg) and TNF-beta (2.0 X 10s 
U/mg) were gifts from Genentech Inc. (South San Francisco, CA). 
E. coli-derived hu-r IL 1 alpha and beta (1 X 10s U/mg), yeast-de- 
rived hu-r IL 2 (2 X 10s U/mg), and yeast-derived hu-r GM-CSF 
(5 X 10’ U/mg) were obtained from Genzyme Corporation (Bos- 
ton, MA). The titer of these cytokine preparations ranged from 
1 X IO3 to 6.6 X 10’ U/ml of phosphate buffered saline and they 
were added directly to fibroblast cultures after dilution to the de- 
sired concentrations with Dulbecco’s Modified Eagle’s medium 
(DME) containing 0.1% human serum albumin. TGF-beta from 
human platelets (> 95% pure) was obtained as a 2.2 X IO” pM solu- 
tion in 20% acetonitrile: 0.1% trifluoroacetic acid from Calbio- 
them Biochemicals (San Diego, CA), and after an initial 1: 10 dilu- 
tion in 4 n&l HCl it was diluted in DME plus albumin and added 
directly to cultures. 
Fibroblast Cultures The normal adult dermal fibroblast lines 
used in this study were previously established using the explant 
method from samples of skin removed during cosmetic surgery. 
Line 1 was derived from the mammary skin of a 35year-old female, 
line 2 from the facial skin of a 52-year-old male, and line 3 from the 
facial skin of a 42-year-old female. The fibroblasts were maintained 
in DME containing 25 mM HEPES, 2 mM glutamine, 100 U/ml 
penicillin, and 100 pug/ml streptomycin plus 10% heat-inactivated 
fetal calf serum (FCS) (Whittaker-MA Bioproducts, Walkersville, 
MA) at 37°C in a 5% COa humidified atmosphere. Fibroblast cul- 
tures were subcultured by trypsinization and used between the sec- 
ond and tenth passages. We have previously reported on the growth 
and collagen production of these fibroblast lines and that they re- 
spond equally well to IFN treatment in early (second) or later 
(ninth) passage [45]. W e h ave similarly found the response of these 
fibroblast lines to treatment with IL 1 and TNF to be independent of 
passage number between the second and tenth passages. 
Assay of Fibroblast Collagen Production Assay of collagen 
production during a 24-h period by steady-state, confluent fibro- 
blasts cultured in the presence of ascorbic acid and no FCS or 10% 
FCS was assessed by 3H-proline incorporation into collagenous pro- 
tein. The use of confluent cultures minimizes growth-related 
events. Freshly trypsinized fibroblasts were plated in triplicate in 96 
well microcultures (0.45 cm* surface area; Microtest III; Falcon 
Labware, Oxnard, CA) at a near confluent density of 25-40,000 
fibroblasts per well in 200 ~1 DME-10% FCS and incubated for 
48 - I20 h to produce a totally confluent monolayer of fibroblasts. 
The medium was then removed and replaced with 200 ~1 DME 
alone or DME plus 10% FCS containing 50 pg/ml ascorbic acid 
with or without cytokines, and incubated for an additional 24,48, 
or 72 h. Cultures were pulsed with 0.5 &i of 3H-proline (31 Ci/ 
mmol; Amersham Corp, Arlington Heights, IL), 50 pg/ml beta- 
aminopropionitrile, and 50 pg/ml ascorbic acid for the final 24 h of 
culture. The 3H-proline incorporation into pepsin-resistant, salt- 
precipitated extracellular collagen was then determined as pre- 
viously described [46-481. 
by 
Briefly, extracellular 3H-proline-labeled collagen was extracted 
the addition of acetic acid-pepsin to the culture media in each 
microwell and purified by successive salt precipitations at acid and 
neutral pH. The final washed precipitate was solubilized in 0.5 M 
acetic acid, incorporated into a scintillation cocktail, and counted in 
a liquid scintillation counter. In our hands this assay yields material 
that is 95% collagenase digestible, and the method isolates less than 
1% of non-collagenous proteins biosynthetically labeled with 3H- 
tryptophan [48]. E ac h experimental condition was done in triplicate 
wells and averaged results are expressed as disintegrations per min- 
ute (dpm) of 3H-collagen per IO3 cells f standard deviation (SD), 
with cell numbers determined by hemocytometer-counting the 
number of trypsin released cells present in a series of identically 
treated microcultures. 
Assay of Fibroblast Glycosaminoglycan Production Micro- 
cultures treated identically to those described above for assay of 
collagen production were used to assess glycosaminoglycan produc- 
tion except they were incubated without beta-aminopropionitrile 
and labeled with 0.5 PCi of 3H-glucosamine (22 Ci/mmol, Amer- 
sham) for the terminal 24 h of culture. The 3H-glucosamine incor- 
poration into cetylpyridinium chloride-precipitated glycosamino- 
glycans in both the culture media and cell layer was then 
determined as previously described [8,49]. Briefly, cellular and su- 
pernatant protein was digested by incubation at 55°C for 4 h after 
the addition of pronase (Calbiochem) to the culture media of each 
microwell. After centrifugation to clear and the addition of carrier 
chondroitin sulfate and hyaluronic acid (Sigma Chemical, St. Louis, 
MO), glycosaminoglycans were precipitated by the addition of ce- 
tylpyridinium chloride to a final concentration of 0.5%. Precipi- 
tated material was collected on glass fiber filters, washed, dried, and 
the 3H-glucosamine-labeled glycosaminoglycans bound to the 
filters quantitated by liquid scintillation spectrometry. Each experi- 
mental condition was done in triplicate wells and averaged results 
are expressed as dpm of 3H-glycosaminoglycan per IO3 cells + SD, 
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with cell numbers determined by hemocytometer-counting the 
number of trypsin released cells present in a series of identically 
treated microcultures. 
Assay of Fibroblast Fibronectin Production Near confluent 
fibroblast cultures were set up by placing 100-160,000 freshly 
trypsinized fibroblasts, contained in 1 ml of DME-10% FCS, into 
24 well microcultures (2.0 cm* surface area; Linbro; Flow Labs, 
McLean, VA) and incubating for 48 - 120 h at 37°C in a 5% CO2 
atmosphere to permit growth to total confluency. Medium was then 
removed and replaced with 0.5 ml fresh DME alone or DME + 
10% FCS containing 50 pg/ m ascorbic acid with or without cyto- 1 
kines and incubated for an additional 24, 48, or 72 h. Supernatant 
medium was removed and the fibronectin content of the medium 
was determined using a commercially available immunoturbidime- 
tric assay kit (Boehringer-Mannheim, Indianapolis, IN). This assay 
uses an antisera to human fibronectin which has minimal cross-reac- 
tivity with bovine fibronectin, allowing the accurate assay of the 
fibronectin content of culture supernatants containing 10% FCS 
after subtraction of a small background value. Each experimental 
condition was performed in triplicate wells, and averaged results 
obtained by measuring the fibronectin concentration of 0.3 ml ali- 
quots of supernatant medium are reported as pg per lo5 cells + SD, 
with cell numbers being determined by counting the number of 
trypsin-released cells per well using a hemocytometer. 
Assay of Fibroblast Collagenase Activity Production 
Twenty-four well microcultures treated identically to those de- 
scribed above for assay of fibronectin production were used to assess 
collagenase activity production. However, terminal 24,48, or 72 h 
incubation were performed in only ascorbic acid supplemented 
DME alone, as FCS interfered with the subsequent assay of culture 
supernatant collagenase activity. The supernatants from these cul- 
tures, after activation by brief trypsin treatment, were then assayed 
for collagenase activity by measuring the solubilization of 3H-la- 
beled rat (type I) collagen fibrillar gels using previously reported 
methods [44,50,51] modified to assay larger volumes of supernatant 
over a longer period of time, in order to accurately quantitate the 
lower levels of collagenase activity produced by control fibroblast 
cultures. 
Briefly, the procollagenase in 1.0 ml of culture supernatant or 
dilutions of supernatant in DME was activated by incubation at 
28°C for 12 min with 50 units of trypsin (DPCC-treated; Sigma), 
followed by the addition of a tenfold excess of soybean trypsin 
inhibitor (Sigma) to inhibit further trypsin activity. 3H-labeled-fi- 
brillar collagen gels were formed by mixing 800~1 of a 1.25 mg/ml 
solution of unlabeled rat tail (type I) collagen (Sigma) in O.OOIN 
acetic acid with 10 ,~l of 3H-propionylated-rat tail collagen (0.51 
mCi/mg; New England Nuclear, Boston, MA) in O.OIN acetic acid 
and neutralizing with 200 ~1 of fivefold concentrated DME. 
Twenty-five microliter (25 pg collagen; 30,000 dpm) aliquots of 
this neutralized solution were then dispensed in 24-well plates (Lin- 
bro) tilted at a 45” angle and allowed to gel at 37°C in a 5% CO, 
humidified atmosphere for 4 h. Formed fibrillar gels adherent to the 
edges of the well bottom were then washed twice with DME and 
incubated for an additional 18 h in 1 ml of DME. After removal of 
this 18-h DME wash, the collagenolytic activity of trypsin-acti- 
vated supernatant samples was then determined by placing 1 .O ml of 
sample in each well and incubating for a further 20 h. Each milliliter 
of fluid was then carefully removed from the wells and subjected to 
scintillation counting to determine the amount of collagen solubi- 
lized from each gel. The collagenase activity of each sample was 
then calculated from the percentage gel lysis by reference to 100% 
digestion caused by 100 units/ml of a highly purified clostridial 
collagenase (Sigma) with 1 .O ml of control fibroblast culture super- 
natant typically causing approximately 20% - 30% gel lysis. Super- 
natants were assayed in triplicate and averaged results are reported as 
mU of collagenase activity per lo5 cells & SD, with 1 .O U defined as 
the amount of collagenase activity digesting 1 .O pg of collagen per 
minute. To ensure that gels were not composed of denatured colla- 
gen, which is digested by other proteolytic enzymes besides colla- 
genase, each batch of gels was tested for sensitivity to digestion by 
50 U/ml of trypsin, which typically caused less than 10% gel lysis 
over a 20-h period. 
RESULTS 
Effect of Cytokines on Fibroblast Collagen Production 
Samples of hu-r cytokines were assayed for effect on the collagen 
production of adult dermal fibroblasts using culture conditions 
(DME plus 10% FCS) identical to those we had previously em- 
ployed to demonstrate IFN-mediated inhibition of collagen pro- 
duction [45]. The use of confluent cultures minimizes growth re- 
lated events, while the use of 10% FCS ensures optimal levels of 
collagen production. Because the optimal collagen production oc- 
curing in the presence of 10% FCS may be 
stimulation by serum factors such as TGF- g 
artially due to direct 
eta [18-201, studies 
were also performed in the absence of FCS to assess the effect of 
cytokines on basal collagen production. 
Cytokines were first tested on fibroblast line 1 using a 48-h treat- 
ment period to determine maximum effective concentrations. As 
detailed in Table I, IL l-alpha and beta and TNF-alpha and beta 
caused concentration-dependent increases in collagen production in 
the absence of FCS but had no effect on collagen reduction in the 
presence of FCS. The reason for ineffective P stimu ation of collagen 
production in the presence of 10% FCS was not investigated, but 
may be related to the ability of IL 1 and TNF to induce the growth 
of confluent fibroblast cultures in the presence but not the absence 
of FCS [25,28]. While we observed that IL 1 and TNF had no effect 
on the growth of confluent microcultures in the absence of FCS, IL 
1 and TNF frequently induced 20% - 30% increases in cell numbers 
Table I. Effect of Cytokines on Collagen Production by 
Dermal Fibroblast Line 1’ 
3H-Collagenb 
(DPM/IO~ Cells * SD) 
Cytokine Concentration 
Dh4E+ 
DME 10% FCS 
None 45 zk 2 119+12 
r IL l-a 1 U/ml 55 * 5 115f2 
10 70+7 llOf4 
2 79 + 2 123 z!z 13 
r IL 1-p :OU/ml 50 + 5 116 f 12 
10 76+5 119f8 
z 91 zk 10 llOf14 
I TNF-a :OU/ml 49 zk 4 125 + 12 
10 55f6 114+4 
102 75 f 8 103 + 15 
10’ 84 * 4 95 f 10 
r TNF-P 1 U/ml 44 f 3 115f20 
10 51 f9 127 f 16 
102 62 f 5 105f8 
104 74 f 7 113f9 
r IL 2 10 U/ml 47 f 4 112f8 
102 43 * 1 105 * 10 
3 
ii U/ml 
46 zk 5 112 f 14 
r GM-CSF 47 f 3 118f8 
102 48 + 1 106 k 12 
3 43 f 2 113 + 15 
r IFN-(u, ii4 U/ml 21 f 3 66 f 6 
TGF-P 103pM 246 k 20 378 + 35 
a Representative experiment showing the effect of 48 h of cytokine exposure on the 
collagen production of adult dermal fibroblast line 1 cultured in the absence and pres- 
ence of FCS as described in Mote&& and Methods. Data were confirmed in two addi- 
tional experiments. 
b Collagen production was assessed by measuring “H-proline incorporation into pep- 
sin-resistant, salt-precipitated extracellular collagen and is expressed as dpm/IO’ 
cells + SD of triplicate determinations. All IFN-aloha, and TGF-beta treatment values . - 
arc significantly~different from untreated control values (Student’s two-tailed t-test: 
P < 0.05) as are treatment values in DME alone for IL 1 alpha and beta at 10 U/ml or 
greater and TNF-alpha and beta at 102 U/ml or greater. All other treatment values are 
not significantly different from untreated control values. 
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Figure 1. Effect of exposure time on cytokine modulation of adult dermal 
fibroblast functions. Confluent cultures of fibroblast line 1 incubated in 
Dh4E without FCS were exposed to 10 U/ml of IL l-beta (solid line) or IO* 
U/ml of TNF-alpha (broken line) for 24.48, or 72 h. Collagen (closed circle), 
glycosaminoglycan (X), fibronectin (closed square) and collagenase activity 
(closed triangle) production were assessed as described in Materials and Method 
and are expressed as percentage of control fibroblast production (100%). 
Control fibroblast values f SD at 24,48, and 72 h were collagen: 49 + 3.3, 
31.9 f 1.7, 24.2 + 0.4 dpm/103 cells; glycosaminoglycan: 43.7 f 2.6, 
39.2 f 1.1,24.9 + 0.2 dpm/103 cells; fibronectin: 0.82 f .04, 1.44 f .06, 
1.98 + .I3 pug/IO5 cells: collagenase activity: 5.24 + .56, 6.88 f .44, 
2.65 f .21 mU/105 cells. All plotted cytokine treatment values are signifi- 
cantly different from untreated control values. (Student’s two tailed t-test: 
P < 0.05) except TNF-alpha at 24 hours. 
over a 48-h period in the presence of 10% FCS. The decreased basal 
collagen production (on a per cell basis) of such post-confluent 
cultures [52] may compensate for any increase induced by IL 1 or 
TNF resulting in no net increase in collagen production when com- 
pared to confluent untreated controls. However, if highly confluent 
microcultures are not used, IL 1 and TNF induce 60%-70% in- 
creases in cell numbers resulting in a net decrease in collagen pro- 
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duction on a per cell basis (data not shown). TNF-alpha has recently 
been reported to decrease the collagen production of infant foreskin 
fibroblasts cultured in 10% FCS [53]. 
At the highest concentrations tested, IL 1 and TNF caused 64% - 
102% increases in collagen production in the absence of FCS. The 
IL Is, however, were more potent stimulators than TNFs, as 10 
U/ml (5.7 PM) of the IL 1s caused 56% - 68% increases, while 100 
U/ml (117 PM) of TNF-alpha or 1000 U/ml (270 PM) TNF-beta 
were required to induce a similar increase in collagen production. In 
contrast to the stimulatory activity of IL 1 and TNF, IL 2 and 
GM-CSF had no effect on collagen production when tested at con- 
centration up to lo3 U/ml either in the absence or presence of FCS. 
A known inhibitor, IFN-alpha,, and a known stimulator, TGF- 
beta, of collagen production were also assayed to confirm the re- 
sponse of our culture and assay systems [ 18 - 20,45,48]. As shown in 
Table I, IFN-alpha, inhibited and TGF-j? stimulated, collagen pro- 
duction in both the absence and presence of FCS, suggesting that 
our system was capable of detecting increases or decreases in colla- 
gen production under both culture conditions. We have not at- 
tempted to determine if type I or type III collagen is more affected 
by IL 1 and TNF treatment. However, considering that known 
modulators of collagen production coordinately effect both type I 
and type III collagen production by dermal fibroblasts [35], our 
results may reflect similar changes. 
To determine the kinetics of the response of fibroblast line 1 to IL 
1 and TNF treatment, we investigated collagen production after 24, 
48, and 72 h cytokine exposure. As shown in Fig 1, in the absence of 
FCS, IL I-beta and TNF-alpha caused progressively greater in- 
creases in collagen production with time. IL l-beta and TNF-alpha 
in the presence of 10% FCS had no effect on collagen production 
(data not shown). 
To ensure that the effects of IL 1 and TNF were not restricted to 
one fibroblast line, the influence of these cytokines was examined 
on two additional adult dermal fibroblast lines. As shown in the 
detail in Table II, fibroblast lines 2 and 3 responded similarly to 
fibroblast line 1, with IL l-alpha and beta and TNF-alpha and beta 
stimulating collagen production in the absence but not in the pres- 
ence of FCS. Because the three fibroblast lines tested were derived 
from skin taken from different anatomical sites (breast, face) of both 
Table II. Effect of Cytokines on Biosynthetic Functions of Dermal Fibroblast Lines 2 and 3’ 
Fibroblast line 2 Fibroblast line 3 
DME+ DME+ 
Assay Cytokine DME 10% FCS DMJ! 10% FCS 
None 26 f 2 48 z!z 4 32+ 1 78 f 7 
Collagen rILl_cr 35 f 1 46 + 4 118 + 13 79 f 8 
(DPM/lOs cells zk SD) r IL 1-B 36 f 2 53 + 8 100 * 11 75 f 2 
r TNF-TV 36 + 3 44 f 4 45 f 2 77 * 5 
r TNF-b 32f 1 44 * 1 45 + 8 74 f 4 
None 61 f4 100 + 13 46 f 7 66 * 2 
Glycosaminoglycan rILl-cz 172 + 18 206 + 12 70 + 5 156 z!z 22 
(DPM/103 cells + SD) r IL 1-B 109 f 6 234 f 28 59 f 2 107 + 12 
r TNF-a 152 f 6 222 z!z 8 99 It 3 123 + 1 
r TNF-j? 150f4 216 + 4 71 f2 80+ 1 
None 1.91 f 0.16 2.34 z!z 0.18 1.77 f 0.06 1.92 rt 0.10 
Fibronectin rILl_cu 1.19 f 0.07 1.68 + 0.12 1.44 f 0.04 1.55 z!z 0.03 
@g/IO5 cells + SD) r IL l-j? 1.36 + 0.03 1.89 + 0.07 1.60 z!z 0.08 1.69 + 0.01 
r TNF-ct 1.12 f 0.16 1.41 f 0.09 1.25 f 0.02 1.42 + 0.06 
r TNF-b 1.16 + 0.09 1.68 f 0.05 1.33 f 0.02 1.22 f 0.03 
None 11.5 * 1.4 NDb 2.2 * 0.4 ND 
Collagenase r IL 1-a 85.7 + 5.9 ND 6.5 f 0.2 ND 
(mu/lo5 cells f SD) r IL I-8 132.6 + 2.0 ND 34.7 +- 0.7 ND 
r TNF-TV 74.3 f 4.1 ND 8.3 f 1.3 ND 
r TNF-/I 80.6 * 5.0 ND 4.9 * 0.7 ND 
* Experiments show the effect on 48 h of cytokine exposure on the biosynthetic functions of adult dermal fibroblast lines 2 and 3 cultured in the absence and presence of FCS. 
Confluent fibroblast cultures were exposed to 10 U/ml of IL l-alpha or beta or 101 U/ml of TNF-alpha or beta and collagen, glycosaminoglycan, fibronectin, and collagenasc 
activity production assessed as described in Materials and Methods. All listed cytokine treatment values are significantly different from untreated control values (Student’s two tailed 
f-test: P < 0.05) except values for collagen production in the presence of FCS. 
b ND: not done. 
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males and females, the data suggest that IL 1 and TNF will similarly TNF-alpha and beta stimulate only the hyaluronic acid production 
affect the collagen production of most adult dermal fibroblast lines. of adult lung fibroblasts [34]. 
Effect of Cytokines on Pibroblast Glycosaminoglycan Pro- 
duction The effect of hu-r cytokines on adult dermal fibroblast 
glycosaminoglycan production was studied using culture conditions 
identical to the collagen assay. Assays were again performed in the 
presence and absence of FCS, as serum factors such as TGF-beta also 
stimulate glycosaminoglycan production [19]. As shown in Table 
III, 48-h treatments with IL l-alpha and beta and TNF-alpha and 
beta caused concentration-dependent increases in the glycosamino- 
glycan production of fibroblast line 1 both in the absence and pres- 
ence of FCS, while IL 2 and GM-CSF were without effect. At the 
highest concentrations tested, IL 1 and TNF caused 84% - 119% 
increases in glycosaminoglycan production in the presence of FCS, 
while in the absence of FCS they caused 102% - 202% increases. As 
found with collagen production IL Is were more potent stimulators 
than TNFs, as 10 U/ml (5.7 PM) of IL l-alpha or beta stimulated as 
much glycosaminoglycan production as 100 U/ml (117 or 27 PM) 
of TNF-alpha or beta. Known modulators of glycosaminoglycan 
production also acted in both the absence and presence of FCS, with 
IFN-alpha2 suppressing production equally well in both systems, 
while TGF-beta caused increases in glycosaminoglycan production, 
which, like IL 1 and TNF, were more significant in the absence 
(320%) than presence (115%) of FCS [19,54]. We have not at- 
tempted to determine which individual types of glycosaminogly- 
cans are affected by the cytokine treatments. However, considering 
that only 50% to 60% of the 3H-glucosamine-labeled glycosamino- 
glycans produced by adult dermal fibroblasts is hyaluronic acid 
[8,36] our results may reflect changes in the production of either 
hyaluronic acid, sulfated glycosaminoglycans, or heparin, although 
As shown in Fig 1, IL I-beta and TNF-alpha also increased the 
glycosaminoglycan production of fibroblast line 1 after 24 and 72 h 
of cytokine exposure in the absence of FCS, with 72 h augmentation 
being less than 48 h values. Similar effects were observed in the 
presence of 10% FCS (data not shown). IL 1 and TNF also stimu- 
lated the glycosaminoglycan production of fibroblast lines 2 and 3 as 
detailed in Table II. 
Effect of Cytokines on Fibroblast Fibronectin Production 
The effect of hu-r cytokines on adult dermal fibroblast fibronectin 
production was studied using culture conditions identical to the 
collagen and glycosaminoglycan assays but employing larger cul- 
tures (24 well plates), as greater than 200 ~1 of supernatant per 
sample was required for subsequent immunoturbidimetric assay of 
fibronectin. Assays were again performed in the presence and ab- 
sence of FCS as serum factors such as TGF-beta also stimulate fibro- 
nectin production [18]. As shown in Table IV, IL l-alpha and beta 
and TNF-alpha and beta caused concentration-dependent decreases 
in the fibronectin production of fibroblast line 1 both in the absence 
and presence of FCS, with IL 1 and TNF being approximately 
equipotent, as 100 U/ml (IL Is: 57 pM; TNF-alpha: 117 pM; TNF- 
beta: 27 PM) of each cytokine caused 35% to 55% inhibition of 
fibronectin production. As with collagen and glycosaminoglycan 
production, IL 2 and GM-CSF were similarly ineffective in modu- 
lating fibroblast fib ronectin production. The two known modula- 
tors of dermal fibroblast functions, IFN-alpha, and TGF-beta, be- 
haved as previously reported with IFN-alpha, having no effect and 
TGF-beta increasing fibronectin production in both the absence and 
presence of FCS [18,54]. 
When the fibronectin production of fibroblast line 1 cultured in 
the absence of FCS was examined after 24,48, or 72 h of IL I-beta or 
TNF-alpha exposure, fibronectin levels were found to be decreased 
by approximately the same amount at each time point (Fig 1). Simi- 
lar effects were observed in the presence of 10% FCS (data not 
shown). As shown in Table II, IL 1 and TNF also depressed the 
fibronectin production of fibroblast lines 2 and 3. Thus in contrast 
to stimulating collagen and glycosaminoglycan production, IL l- 
alpha and beta, and TNF-alpha and beta inhibit fibronectin produc- 
tion. 
Table III. Effect of Cytokines on Glycosaminoglycan 
production by Dermal Fibroblast Line 1’ 
3H-Glycosaminoglycanb 
(DPM/103 Cells f SD) 
Cytokine Concentration 
DMJ!+ 
DME 10% FCS 
None 
r IL l-a 
r IL 1-p 
r TNF-a 
r TNF-P 
r IL 2 
r GM-CSF 
r IFN-a, 
TGF-/? 
1 U/ml 
10 
z 
:OU/ml 
10 
102 
1 U/ml 
10 
102 
104 
1 U/ml 
10 
102 
10’ 
10 U/ml 
102 
103 
10 U/ml 
102 
3 
:i4 U/ml 
10’ pM 
49 f 2 
53 f 4 
72 f 5 
132f2 
48 * 6 
78 + 7 
148 & 8 
46 + 5 
57 f 4 
75 + 9 
121 f 4 
47 f 2 
64 f 7 
82 f 9 
99 f 2 
51 f5 
47 -t 3 
48 + 4 
50 * 4 
52 f 6 
49 f 2 
28 f 3 
206 f 25 
121 f 4 
130 + 6 
190 f 13 
261 f 18 
127 + 5 
207 + 17 
232 f 18 
131+ 10 
145 * 7 
202 f 7 
266 * 25 
107 f 2 
120* 11 
164 + 12 
223 + 17 
114 & 11 
125 f 5 
132 f 10 
116+4 
127f4 
144 * 5 
56 f 3 
260 f 12 
a Representative experiment showing the effect of 48 h of cytokine exposure on the 
glycosaminoglycan production of adult dermal fibroblast line 1 cultured in the absence 
and presence of FCS as described in Morerinls and Methods. Data were confirmed in three 
additional experiments. 
b Glycosaminoglycan production was assessed by measuring ‘H-glucosamine incor- 
poration into cetylpyridinium chloride precipitated material in both culture media and 
cell layer and is expressed as dpm/lO’cells _+ SD of triplicate determinations. All listed 
treatment values are significantly different from untreated control values (Student’s 
two-tailed t-test: P < 0.05) except IL l-alpha, beta and TNF-alpha and beta at 1 U/ml, 
TNF-beta 10 U/ml in 10% FCS and all concentrations of IL 2 and GM-CSF. 
Earlier studies done with synovial or infant foreskin fibroblasts 
both agree and conflict with our observation that IL 1 decreases 
adult dermal fibroblast fibronectin production. Earlier studies per- 
formed with partially purified mononuclear cell-derived IL 1 prepa- 
rations showed increases in extracellular fibronectin production by 
synovial fibroblasts [26]. However, such crude IL 1 preparations 
may have contained other mononuclear cell products, such as TGF- 
beta, which could have masked the inhibitory effect of IL 1 by 
stimulating fibronectin production [ 181. This seems likely as hu-r- 
IL l-alpha and beta have recently been reported to decrease the 
extracellular fibronectin produced by infant foreskin fibroblasts 
without affecting fibronectin mRNA levels [55], and ultrapure 
preparations of mononuclear cell-derived IL 1 have been shown to 
decrease synovial fibroblast fibronectin production [56]. 
Effect of Cytokines on Fibroblast Collagenase Activity Pro- 
duction We also investigated the influence ofcytokines on the net 
collagen degrading enzymatic activity released by cultured adult 
dermal fibroblast in order to determine if cytokines play a role in 
dermal connective tissue degradation. Our assay of trypsin-activat- 
able collagenolytic activity measures net collagenase activity, as fi- 
broblast supernatant media contains both the enzyme collagenase 
and its inhibitor, tissue inhibitor of metalloproteinases. and both 
have been shown to be induced by IL 1 [55]. The results illustrated 
in Table V show that fibroblast line 1 cultured in the absence of FCS 
produced significantly elevated quantities of collagenase activity 
when treated for 48 h with IL l-alpha and beta and TNF-alpha and 
beta, but unaltered levels of collagenase activity when treated with 
IL 2 or GM-CSF. The increases in collagenase activity induced by 
IL 1 and TNF were concentration dependent with the highest 
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Table IV. Effect of Cytokines on Fibronectin Production by 
Dermal Fibroblast Line 1’ 
Table V. Effect of Cytokines on Collagenase Activity Produced 
by Dermal Fibroblast Line 1’ 
Fibronectinb 
(pg/lOs Cells + SD) Cytokine 
Cytokine Concentration 
DME+ None 
DME 10% FCS r IL l-a 
None 
r IL l-a 
r IL l-j? 
r TNF-a 
r TNF-/I 
r IL 2 
r GM-CSF 
r IFN-(Y, 
TGF-B 
1 U/ml 
10 
102 
1 U/ml 
10 
102 
1 U/ml 
10 
102 
4 
:OU/mI 
10 
102 
IO’ 
10 U/ml 
102 
IO’ 
10 U/ml 
102 
3 
ii4 U/ml 
IO3 pM 
1.80 + .04 
1.85 z!z .23 
1.12 f .I6 
0.86 f .05 
1.78 + .18 
1.18 + .04 
0.93 + .I0 
1.65 f .20 
1.20 f .I4 
1.05 f .07 
0.94 + .09 
1.75 f .I4 
1.45 * .I3 
1.17 + .I0 
1.06 + .05 
1.73 + .I9 
1.84 & .I7 
1.92 Ifr .I4 
1.59 * .08 
1.75 f .I3 
1.72 + .I0 
1.78 + .09 
3.06 f .26 
2.82 + .I7 
2.40 f .I4 
1.69 + .09 
1.44 f .08 
2.87 f .19 
2.03 + .05 
1.29 f .07 
2.62 f .15 
1.82 f .06 
1.69 f .I5 
1.52 + .I1 
2.99 + .25 
2.03 f .I9 
1.57 f .I5 
1.21 f .I3 
2.65 + .I9 
3.21 + .I4 
2.93 + .26 
2.76 + .23 
3.10 f .35 
2.92 + .I7 
3.01 f .20 
4.65 f .38 
1 Representative experiment showing the effect of 48 h of cytokine exposure on the 
fibronectin production of adult demxd fibroblast line 1 cultured in the absence and 
presence of’FCS as described in Mater& and Methods. Data was confirmed in two 
additional experiments. 
b Fibronectin production was assessed by measuring the quantity of fibronectin 
present in fibroblast culture supematants using an immunoturbidimetric assay and is 
expressed as ug/105 cells + SD of triplicate determinations. The TGF-beta treatment 
value and treatment values for IL 1 &ha and beta and TNF-&ha and beta at 10 U/ml 
or greater are significantly different fr:m untreated control &es (Student’s two-tailed 
t-test: P < 0.05). All other treatment values are not significantly different from un- 
treated control values. 
concentrations tested causing 12.3- to 18.8-fold increases in pro- 
duction. The IL 1 appear to be more potent inducers than TNF as 
lo-100 U/ml (5.7-57 PM) of IL 1 alpha or beta stimulated as 
much collagenase production as lo4 U/ml (11,700 or 2,700 PM) of 
TNF-alpha or beta. Moreover, IL 1 and TNF were much more 
effective stimulators of collagenase activity production than of col- 
lagen or glycosaminoglycan production, as even 1 U/ml induced 
2.5- to 9.1-fold increases in collagenase activity. These increases 
were also much greater than those caused by a higher concentration 
of IFN-alphaa, another reported stimulator of collagenase activity 
production [54]. 
The significant increases in net collagenase activity released by 
fibroblast line 1 were time dependent, as IL l-beta and TNF-alpha 
treatment caused progressively greater enhancement of collagenase 
activity production after 24,48, and 72 h of cytokine treatment (Fig 
1). Fibroblast lines 2 and 3 also responded to IL 1 and TNF treat- 
ment by producing elevated levels of collagenase activity as shown 
in Table II. 
DISCUSSION 
The purpose of this study was to clarify the role played by immuno- 
logically derived cytokines in initiating dermal fibrosis by investi- 
gating the effect of cytokines on some dermal fibroblast functions 
that are known to be activated during fibrotic responses; namely, 
collagen, glycosaminoglycan, fibronectin, and collagenase activity 
production. Our results suggest that certain immunologically de- 
rived cytokines, IL I-alpha and beta and TNF-alpha and beta, may 
lay a major role in regulating dermal fibrosis, while other cyto- 
“k. mes, IL 2 and GM-CSF, likely play little or no role in dermal 
fibrosis, as they altered none of the fibroblast functions studied. This 
Concentration 
Collagenaseb 
(mu/lo5 Cells + SD) 
r IL 1-p 
r TNF-c~ 
r TNF-/I 
r IL 2 
r GM-CSF 
r IFN-a, 
1 U/ml 
10 
102 
1 U/ml 
10 
102 
1 U/ml 
10 
102 
10’ 
1 U/ml 
10 
102 
IO’ 
10 U/ml 
102 
3 
:i U/ml 
102 
10s 
IO4 U/ml 
3.18 f .32 
32.4 + 2.1 
56.2 f 4.7 
62.4 f 5.6 
21.0 zk 3.1 
40.8 f 4.6 
59.9 * 4.3 
12.5 f 1.5 
18.1 f 1.3 
31.6 zk 4.1 
57.1 f 6.3 
7.91 + .30 
12.2 f 1.3 
19.2 f .32 
39.3 f 5.6 
3.10 f .29 
3.08 + .36 
3.34 + .35 
3.20 + .25 
3.28 f .34 
2.80 f .41 
5.60 f .43 
1 Representative experiment shows the effect of 48 h of cytokine exposure on the 
collagenase activity production of adult dermal fibroblast line 1 cultured in DME 
without FCS as described in Materials and Methods. Data were confirmed in two addi- 
tional experiments. 
b Collaeenase activitv of trvosin-activated fibroblast cuINre suxmatants was as- 
sessed by &lubilization bf “H-(abeled rat (type I) collagen fibrillar g;ls and is expressed 
as mU/lOs cells + SD of triplicate determinations. All listed cytokine treatment values 
are s&nificantly different f;om untreated control values (S&dent’s two-tailed t-test: 
P < 0.05) except all concentrations of IL 2 and GM-CSF. 
latter concept is further supported by a previous report demonstrat- 
ing that IL 2 also has no effect of dermal fibroblast proliferation [25]. 
Similarly, several previous reports support our observation that IL 
I-alpha and beta and TNF-alpha and beta increase collagen, glyco- 
saminoglycan, and collagenase activity production [26,27,34,41- 
44,55,57] but decrease fibronectin production [55,56]. However, 
the majority of these previous investigations were performed on 
infant foreskin, lung, or synovial fibroblasts and chondrocytes 
rather than on adult dermal fibroblasts, and often employed mono- 
nuclear cell-derived IL 1 and TNF preparations of low specific 
activity, rather than the high specific activity samples of r-IL I- 
alpha and beta or r-TNF-alpha and beta used in this report. Our 
results, therefore, appear to be the first reporting that high specific 
activity samples of hu-r-IL I-alpha and beta and TNF-alpha and 
beta increase the production of collagen, glycosaminoglycan, and 
collagenase activity but decrease the production of fibronectin by 
cultured human adult dermal fibroblast, although hu-r IL 1 has 
recently been shown to increase human infant foreskin fibroblast 
production of collagen and collagenase activity [29,55]. This report 
also confirms previous investigations performed on dermal fibro- 
blasts using lower specific activity in IL 1, in that mononuclear 
cell-derived preparations of IL 1 (approximately 25% IL I-alpha, 
75% IL I-beta) have been reported to increase the production of 
collagenase activity and collagen by infant foreskin or adult dermal 
fibroblasts [29,44,57], while similarly naturally derived TNF-alpha 
preparations have been shown to increase infant foreskin fibroblast 
collagenase production [29]. While these previously reported ob- 
servations could possibly have been ascribed to spurious contami- 
nants in naturally derived cytokine preparations, this report 
strongly suggests that IL l-alpha and beta and TNF-alpha were the 
molecules responsible for these previously observed activities. 
Our finding that IL I-alpha and beta and TNF-alpha and beta 
have an identical spectrum of activities on dermal fibroblasts agrees 
well with the shared activities of these two mediators in other bio- 
logic systems, as has been recently reviewed [58]. Because IL 1 and 
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TNF lack homology and act through separate receptors [58], the 
reason for their overlapping activities in any biologic system is cur- 
rently uncertain. However, recent reports suggest that TNF-alpha 
may act by inducing IL 1 production, which could then act in an 
autocrine manner on the targeted cells [59,60]. Whether TNF-beta 
also induces IL I production has not yet been determined but TNF- 
alpha and beta do bind to the same cell surface receptor (reviewed in 
Ref 58). Such a mechanism may explain why TNF-alpha and beta 
were approximately a log-fold less potent that IL I-alpha and beta in 
modulating three of the four fibroblast functions we studied. In 
contrast, IL I-alpha and IL I-beta, which have only 26% homology 
but act through the same receptor (reviewed in Ref 58), were found 
to be equipotent in modulating all four of the fibroblast functions 
we studied. These findings are in agreement with a previous assess- 
ment of the activities of IL l-alpha and beta in three other bioassays 
1611. 
Our findings reveal that IL 1 and TNF differentially regulate 
cultured adult dermal fibroblast functions and suggest that these 
cytokines could play both an anabolic and a catabolic role in dermal 
connective tissue metabolism during fibrotic responses. However, 
because our results indicate that after 48-h cytokine exposure colla- 
gen production at its maximum is increased only 64% - 102% while 
net collagenase activity is increased by 1230% - 1880%, IL 1 and 
TNF would likely have a net catabolic effect in situ, where, unlike in 
tissue culture, latent procollagenase is spontaneously activated by 
other mediators such as plasmin. Similarly, the increased glyco- 
saminoglycan production we have observed with IL 1 and TNF 
treated fibroblasts (maximum increases: 102% -202%) may be 
dominated by increases in proteoglycanase activity, which report- 
edly ranges up to 490% after stimulation of synovial or dermal 
fibroblasts or chondrocytes by mononuclear-cell-derived prepara- 
tions of IL 1 [43,62]. The significant stimulatory effect of IL l- 
alpha and beta, and TNF-alpha and beta on the production of colla- 
genase and proteoglycanase activities, along with the observed 
direct inhibition of dermal fibroblast fibronectin production, 
strongly suggest that in addition to stimulating fibroblast growth, 
these cytokines act selectively to activate the catabolic functions of 
dermal fibroblasts, and thus, they likely play predominately a cata- 
bolic role in ritu during dermal fibrotic responses. While fibroblasts 
with a catabolic phenotype have yet to be isolated from dermal 
fibrotic tissue, it is speculated that such fibroblasts play a major role 
in connective tissue matrix remodeling during the later stages of 
dermal wound repair [ 121. IL 1 and TNF, therefore, may play a role 
in the progression of dermal wound repair from the earlier anabolic 
granulation-tissue phase to the later catabolic matrix remodeling 
phase by converting the anabolic phenotype fibroblasts of the gran- 
ulation tissue phase to the catabolic phenotype fibroblasts thought 
to be present in the matrix remodeling phase. 
Because IL 1 and TNF treated fibroblasts appear to have a cata- 
bolic phenotype, it is thus unlikely that these cytokines are the 
mediators responsible for inducing the anabolic phenotype fibro- 
blasts isolated from sites of pathologic dermal fibrosis, such as keloid 
and scleroderma skin [3 - 91. However, refractoriness to IL 1 or TNF 
associated mechanisms may be involved in the pathogenesis of scle- 
roderma as both the collagen and procollagen mRNA production by 
scleroderma fibroblasts and the glycosaminoglycan production of 
rabbit granulation tissue fibroblasts have recently been shown to be 
unresponsive to treatment with low concentrations of mononuclear 
cell-derived IL 1 [11,57]. When these reports [ 11,551 are considered 
along with the hypothesis that fibroblast stimulation by IL 1 or 
TNF may be required for progression from the anabolic granulation 
tissue phase of dermal wound repair to the catabolic matrix-remod- 
eling phase, it suggests that normal granulation tissue fibroblast 
acquire in situ responsiveness to IL 1 or TNF and convert to a 
catabolic phenotype but scleroderma fibroblasts fail to make a cata- 
bolic conversion resulting in the prolonged and excessive in situ 
deposition of dermal connective tissue that is the hallmark of sclero- 
derma. While such a concept is attractive, more work is clearly 
needed before the effect of cytokine-mediated fibroblast activation 
on dermal fibrosis is fully elucidated. 
We wish to thank the Schering Corporation for the gift of hu-r IFN-alpha, and 
Genentech, Inc., for the gift of hu-r TNF-alpha and beta. 
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